By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GenMark Diagnostics, formerly known as Osmetech, today said that its US initial public offering has been priced at $6 per share, down from an earlier range of $8 to $10.

The company, which concurrent with the IPO changed its name to GenMark Diagnostics, is offering 4.6 million shares, and said that it expects trading to begin today on the Nasdaq Global Market under the symbol "GNMK."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.